Article

From The American Journal of Managed Care, "On the Horizon for Multiple Myeloma"

This article-written by Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD-highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials.

This article—written by Michael Marlan Mohundro, PharmD, and Brice Labruzzo Mohundro, PharmD—highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials. The new regimens discussed include proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors.

See the article, “On the Horizon for Multiple Myeloma,” from The American Journal of Managed Care in its entirety here.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com
Austin Texas | Image credit: Kevin Ruck - stock.adobe.com